Pharmaceuticals - Mexico

Mexico

The Pharmaceuticals market in Mexico is expected to reach a revenue of US$7.28bn in 2024.
The largest market in the country is Oncology Drugs, with a projected market volume of US$1.37bn in the same year.
The revenue is anticipated to grow at an annual growth rate (CAGR 2024-2028) of 6.00%, resulting in a market volume of US$9.19bn by 2028.
In comparison to other countries, United States is projected to generate the highest revenue of US$636.90bn in 2024.
Mexico's pharmaceutical market is experiencing a surge in demand for generic drugs due to increasing healthcare costs.

Key regions: United States, China, Germany, Japan, Europe

Definition:
The Pharmaceuticals market covers remedies used to cure, treat, prevent, and diagnose diseases. These small molecule drugs or biologic medical products may be called drugs, medications, or medicines. Prescription drugs and over-the-counter (OTC) drugs are both included. Depending on the regulations in each country, these products are provided by pharmacies, hospitals, physicians, and/or drug stores, and/or they can be bought elsewhere. They may be administered in the form of pills, capsules, gels, ointments, injections, infusions, lozenges, or aerosols/sprays.

Structure:
The market is subdivided into Oncology Drugs, Anti-Diabetes Drugs, Anti-Rheumatic Drugs, Vaccines, Dermatological Drugs, Antiviral Drugs, Immunosuppressants, Bronchodilator Drugs, Sensory Organ Drugs, Anti-Hypertensive Drugs, Anti-Coagulants, Anti-Fibrinolytic Drugs, Multiple Sclerosis Drugs, Lipid-Lowering Agents and Other Pharmaceuticals. The Pharmaceuticals market is organized in markets that cover drugs used in specific medical fields, i.e., medicines for a specific disesase or a certain type of medicine. They include original brands, biosimilars, generics, and orphan drugs.The Oncology Drugs market covers pharmaceutical products specifically developed for the treatment and management of various cancers. The Anti-Diabetes Drugs market covers medications designed to manage blood glucose levels and improve insulin sensitivity in individuals with diabetes. The market Anti-Rheumatic Drugs includes pharmaceuticals specifically developed to alleviate symptoms, reduce inflammation, and modify the progression of rheumatic diseases. The Dermatological Drugs market covers pharmaceuticals formulated to treat and manage a wide range of skin conditions such as eczema, acne, and rosacea. The Antiviral Drugs market includes medications designed to treat viral infections and reducing the severity and duration of symptoms. The Immunosuppressants market covers pharmaceuticals that suppress the immune system's activity. The Bronchodilator Drugs market covers pharmaceuticals designed to relax and widen the airways in the lungs. The Sensory Organ Drugs market covers pharmaceuticals targeting the treatment of disorders and conditions affecting sensory organs such as the eyes, ears and nose. The Anti-hypertensive Drugs market covers pharmaceuticals designed to lower blood pressure levels. The Anti-Coagulants Drugs market covers pharmaceuticals developed to prevent the formation of blood clots or to dissolve existing clots. The Anti-Fibrinolytics Drugs market covers pharmaceuticals designed to inhibit the breakdown of blood clots. The Multiple Sclerosis Drugs market covers pharmaceuticals aimed at managing and modifying the course of multiple sclerosis. The Lipid-Lowering Agents market covers pharmaceuticals developed to reduce levels of cholesterol and other lipids in the blood. The Other Pharmaceuticals market provides information on additional specialties that are not covered by the main markets.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novartis, Roche, Pfizer, Merck & Co, Johnson & Johnson, AbbVie, Sanofi.

Market

Region

Region comparison

Currency

Analyst Opinion

The Pharmaceuticals market in Mexico has been experiencing growth in recent years, with a steady increase in demand for prescription drugs and over-the-counter medications.

Customer preferences: Mexican consumers are becoming more health-conscious and are willing to invest in their well-being. This has led to an increase in demand for preventative medications and supplements, as well as prescription drugs for chronic conditions such as diabetes and hypertension. Additionally, there is a growing interest in alternative medicine and natural remedies, which has created opportunities for companies offering these products.

Trends in the market: One of the main trends in the Mexican Pharmaceuticals market is the increasing use of e-commerce platforms to purchase medications. This trend has been accelerated by the COVID-19 pandemic, which has led to a rise in online shopping across all industries. Another trend is the growing importance of generic drugs, which are more affordable than brand-name medications and are becoming increasingly popular among consumers.

Local special circumstances: Mexico has a large population with a high prevalence of chronic diseases such as diabetes and hypertension. This has created a significant demand for prescription medications, particularly in rural areas where access to healthcare is limited. Additionally, the Mexican government provides free healthcare to a large portion of the population, which has led to a high demand for affordable medications.

Underlying macroeconomic factors: Mexico's pharmaceutical market is expected to continue growing due to several macroeconomic factors. The country has a large and growing middle class with increasing purchasing power, which is driving demand for healthcare products and services. Additionally, Mexico has a young and growing population, which is expected to increase demand for healthcare in the coming years. Finally, the Mexican government has implemented policies to encourage foreign investment in the pharmaceutical sector, which is expected to further stimulate growth in the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.